TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Couples Satisfaction Index (CSI-32)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Concentration of DXd in brain metastasis tumor tissue
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: BUP treatment uptake
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Change from baseline in seizure frequency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change from baseline in the number of generalized spike-wave discharges (GSWD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in gamma frequency waves during EEG
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Incidence of stimulation-related adverse symptoms and side effects
Endpoint domain: Adverse events/effects
Primary endpoint: Changes in functional brain connectivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Reduction of calcium density in the Region of Interest (ROI) of the vessel
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: incidence of proximal radial artery occlusion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: incidence of hematoma/bleeding
Endpoint domain: Adverse events/effects
Primary endpoint: Peak Forced Expiratory Volume (FEV1)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Compliance percentage
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: H. pylori prevalence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: H. pylori resistance profiles
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Complete remission of moderate to severe dysplasia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Binge Eating Disorder Symptom Severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Response to treatment according to IGA index score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: intraprocedural technical success
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: rate of sterile site bacterial infections
Endpoint domain: Adverse events/effects
Primary endpoint: Change from baseline in Saliva Check mutans test at 52 weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: Oral health outcomes
Primary endpoint: Change from baseline in the number of teeth with each element of PUFA index at 52 weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: Oral health outcomes
Primary endpoint: Change from baseline on the 5 point plaque index at 52 weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: Oral health outcomes
Primary endpoint: Change in comprehension sub-test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in production sub-test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in narrative language ability index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Diagnostic performance of EDIT-B signatures
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Curve From Time 0 to Infinity (AUC0-inf) of Efinopegdutide
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to Maximum Concentration (Tmax) of Efinopegdutide
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cognitive and psychological disorders
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change in brain muscarinic receptor occupancy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change from Baseline on Tiered Fidelity Inventory (TFI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change Over Time on Interconnected Systems Framework Implementation Inventory (ISFII)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change Over Time on Universal Fidelity Tool (UFT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Medical Mistrust
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in Trust in Health Information
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in Patient Knowledge
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change in Clinical Trial Participation Decision-Making Self-Efficacy
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: optimal coverage of Bystander tumor volume (BTV)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Total Opioid Usage
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adoption of ProMuscle
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Fidelity of ProMuscle
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Change in Health Assessment Questionnaire Disability Index (HAQ-DI)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Total amount of rescue pain medication required
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Incidence and severity of treatment-related MAAEs
Endpoint domain: Adverse events/effects
Primary endpoint: Maximum tolerated dose(s) (MTD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety profile of OT-A201
Endpoint domain: Adverse events/effects
Primary endpoint: Change of influenza viral RNA loads from baseline at the end of treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to Discontinuation of Treatment
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Proportion of subjects achieving fecal disimpaction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Change in Heart Rate (HR) from supine to standing (DeltaHR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Physical functioning related to advanced cancer
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Cachexia grade
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Skin Conductance Algesimeter Index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change of the maximum tendon thickness
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Change of the hypoechogenicity of the common extensor tendon
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Change of the heterogeneity of the common extensor tendon
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Change of the neovascularity of the common extensor tendon
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Change of the bone abnormality of the lateral epicondyle
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Number of patients who discontinue AZD0022 due to toxicity
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Change in Adipose Pro-inflammatory T Helper Type 1 Cell Percentages
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in Liver Steatosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Wingate Anaerobic Test performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Average pain score in the 24-hour post-operative period
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Measurement of interleukin-6
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Motility
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Artefacts
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mucosal Evaluation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Overall Diagnostic Impression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Columella Deviation Angle
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Nostril Width on the cleft side
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Device survival rates
Endpoint domain: Mortality/survival
Primary endpoint: Patient satisfaction of penile prosthesis
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Maximum Observed Plasma Concentration for Bismuth
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Plasma Concentration-time Curve During a Dosing Interval τ for Bismuth
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total Amount of Bismuth Excreted in Urine During a Dosing Interval τ for Bismuth
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Work-related Acceptance and Action Questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: The Social Adjustment Scale-Self Report
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Work-Family Conflict Scale
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Maximum-tolerated dose (MTD) or Recommended Phase 2 dose (RP2D)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean absorbed dose ratio between protected and unprotected liver
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: MRC at 6h
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: MRC at 24h
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: MRC at 48h
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Severe HO Formation
Endpoint domain: Adverse events/effects
Primary endpoint: Proportion of responders to treatment
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Frequency of resident memory lymphocytes in the nasal mucosa
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in nail dystrophy (Nail Psoriasis Severity Index)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in nail dystrophy (Physician-Assessed Global Improvement)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Median number of days of oral morphine medication administered
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Self-Leeds Assessment of Neuropathic Symptoms & Signs (S-LANSS) Pain Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: The Hospital Anxiety and Depression Scale (HADS) Score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Incidence of vulvovaginal GVHD
Endpoint domain: Adverse events/effects
Primary endpoint: Sitting pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Six Minute Walk Test at 3 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Timed Up and Go (TUG) Test at 3 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Action Research Arm Test (ARAT) at 3 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in 10 Meter Walk Test at 3 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Overall proportion of patients with EGFRm
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Proportion of EGFRm in Pathologic Stage
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Duration of bloodstream infection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Proportion of Successful Contacts
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Proportion needing follow-up care
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Depression score (CES-D)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: SARS-CoV-2 virus reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Rate of COVID-19 vaccine completion
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Rate of COVID-10 booster vaccine uptake
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Incidence of post dural puncture headache
Endpoint domain: Adverse events/effects
Primary endpoint: Change from baseline lower extremity muscle strength at 8 weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Change from baseline upper extremity muscle strength at 8 weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Change from baseline aerobic endurance at 8 weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline lower extremity flexibility at 8 weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Change from baseline upper extremity flexibility at 8 weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Quality of life changes in breast cancer survivors
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Satisfaction of the relationship between couples
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Retainer failure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of patients diagnosed with organic upper gastrointestinal diseases
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: alteration of ultrasound-guide corrected GIRD
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: alteration of posterior capsular thickness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Success at first intravenous catheter insertion attempt
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Percent time in range from continuous glucose monitor
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: total deviation between Conventional auricular impression and digital impression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in patient reported insomnia symptoms
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Change in Periodontal pocket depth measured in mm
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Human Factors
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Colonoscope Control
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Device Usability 1
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Device Usability 2
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Sensitivity of EEG for diagnosis of ICANS
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: ICEMS expertise score - Learning during practice tasks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ICEMS expertise score - Technical skill transfer
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in quality of life as measured by the KCCQ changes
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Participant enrollment rates (%)
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Participant retention rates (%)
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Change in acceptability of nutrition supplements
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Traumatic Injuries Distress Scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: BOLD responses to self vs. externally generated speech
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: BOLD responses related to pre-speech auditory modulation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: EEG responses to self vs. externally generated speech
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Global Executive Composite T-score
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Genetic mutations of cancer
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Incidence and Frequency of Treatment-Emergent Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Prevalence of undiagnosed fatty liver disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Prevalence of obstructive sleep apnoea
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Changes in halitosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in microbiota compositions of subgingival microbial and plaque sampling
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in microbiota composition in saliva
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in microbiota composition in faeces
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in total antioxidant capacity (TAC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in hydrogen sulfide production capacity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prediction of SCID-5
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Duration of analgesia until first analgesic request
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Brief Pain Inventory Score (Item 5)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: TBS Modulation Effect
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in motor evoked potential
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: RSV A serum neutralizing antibody titers at 28 days post dose 2
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: RSV B serum neutralizing antibody titers at 28 days post dose 2
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Presence of unsolicited systemic adverse events reported in the 30 minutes after each vaccination
Endpoint domain: Adverse events/effects
Primary endpoint: Intentions to adhere to colorectal cancer screening recommendations
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Intentions to adhere test preference indication
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Number of device and procedure-related adverse events and serious adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Mean change on aided word recognition in the unilateral CI alone listening condition
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean change on AzBio sentences in noise
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Height/Length
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Countable Motor Seizures
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: Time spent on medication related processes
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Feasibility as assessed by survey
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Safety and tolerability of PMN310
Endpoint domain: Adverse events/effects
Primary endpoint: Biomarker response to PMN310
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fear of Cancer Recurrence-7
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: PROMIS Emotional Distress: Anxiety
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: PROMIS Emotional Distress: Depression
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Functional Assessment of Chronic Illness Therapy-General (FACT-G): Overall
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Functional Assessment of Chronic Illness Therapy-General (FACT-G): Physical
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning